Where does Cyprumed rank among its competitors?

Cyprumed ranks 240th amongst 2094 active competitors, of which 114 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was AstraZeneca, which secured $6.05M in Jul, 2025.

Who are the top competitors of Cyprumed?

Cyprumed's top competitors include AbbVie, Merck and Gilead. Among them, AstraZeneca secured the most recent funding round in July, 2025.

Cyprumed - 2026 Company Profile & Competitors

Cyprumed is an unfunded company. It operates as a Developer of oral peptide and BCS Class IV drug delivery technologies. Cyprumed has not raised any funding yet. The company has 2094 active competitors, including 114 funded and 219 that have exited. Its top competitors include companies like AbbVie, Merck and Gilead.

Company Details

Developer of oral peptide and BCS Class IV drug delivery technologies. It develops proprietary technology platforms for the oral administration of therapeutic peptides and Biopharmaceutics Classification System injectable (BCS Class IV) drugs. The company offers multiple oral drug delivery platforms, enabling enhanced bioavailability of APIs. Its technology is designed for ease of production and scalability, while meeting regulatory requirements. Collaborations with pharmaceutical partners are a key aspect of the business model.

Key Metrics

Stage

Unfunded

Ranked

240^th among 2094 active competitors

Similar Companies

AbbVie & 2088 more

View Cyprumed's full profile

Cyprumed has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cyprumed include AbbVie, Merck and Gilead. Here is the list of Top 10 competitors of Cyprumed, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Berkshire Hathaway, Alcor Fund & 10 others	84/100
2nd	Merck 1891, Rahway (United States), Public	Manufacturer of pharmaceutical products	-	Bill & Melinda Gates Foundation, Berkshire Hathaway ... & 11 others	83/100
3rd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	BB Biotech, Jindal Ventures & 18 others	82/100
4th	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	80/100
5th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	77/100
6th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	76/100
7th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Western Technology Investment, Alcor Fund ... & 17 others	76/100
8th	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	72/100
9th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	Gilde Healthcare, SoftBank Group & 12 others	71/100
10th	Pfizer 1849, New York City (United States), Public	Provider of pharmaceutical products for multiple disease treatments	-	Berkshire Hathaway, Alcor Fund & 16 others	71/100
240th	Cyprumed Unfunded	Developer of oral peptide and BCS Class IV drug delivery technologies	-	-	33/100